NCT05309733
Source recordAI-normalized
A Long-term Follow-up Study of Patients Who Received VOR33
A Long-term Follow-up Study of Patients Who Received VOR33 is a registry-stage clinical asset sponsored by Vor Biopharma in Leukemia, Myeloid, Acute. SEO and diligence focus: VOR33, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Leukemia, Myeloid, Acute
Modality: cell therapy
Target: VOR33
Sponsor: Vor Biopharma
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: VOR33
View original source fields
Condition raw: Leukemia, Myeloid, Acute
Condition normalized: Leukemia, Myeloid, Acute
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: VOR33
Target normalized: VOR33